OR WAIT null SECS
Mark Altmeyer is now president and CEO of Otsuka American Pharmaceutical, Inc., (Rockville, MD and Princeton, NJ) replacing Dean R. Haubrich, who will now be chairman of the board. Altmeyer joins Otsuka from Bristol Myers Squibb, where he was SVP, global commercialization for oncology.
Two reassignments are occurring at Eli Lilly (Indianapolis): Alex Azar III, currently SVP of corporate affairs and communications, will be head of the US Business-to-Business organization and Puerto Rico, overseeing public payer, managed care and wholesaler operations in the US and sales and marketing in Puerto Rico. And Jack Bailey, current US SVP of account-based markets, will take on oversight of the US diabetes business unit while continuing to manage Lilly USA oncology and cardiovascular teams, and Lilly Hospital Group. Meanwhile, Anthony (Tony) Murphy, PhD, SVP of human resources at Lilly, will be retiring in April after nearly three decades in human resources at the company. No successor was named.
Jennifer A. Doudna, PhD, has left the faculty of University of California, Berkeley, to become the VP, discovery research, at Genentech, Inc. (South San Francisco), where she will oversee the departments of protein chemistry and structural biology.
After 20 years in the faculty of Harvard and Harvard Medical School, Dr. D. Gary Gilliland has joined Merck & Co. as SVP of Merck Laboratories and oncology franchise head. Dr. Gilliland is replacing Dr. Stephen H. Friend, who is leaving Merck to develop an open-access database for international collaboration, which will be supported by Merck.
Bristol-Myers Squibb (New York) is making a number of organizational changes and appointments. Lamberto Andreotti is now president and chief operating officer, and was elected to the company’s board of directors. Previously, he was EVP and COO. Jen-Marc Huet has been promoted to EVP and CFO, and will oversee strategy and productivity efforts in additional to finance. Also: Anthony Hooper has been named president, Americas; Beatrice Cazala is president, emerging markets and Asia-Pacific; Carlo De Notaristefani is president, technical operations and global support; and Giovanni Caforio is SVP, global and US oncology.
Catalent Pharma Solutions (Somerset, NJ) has appointed John Chiminski president, CEO and director. Interim president George Fortiades will step down but remain chairman of the board. Previously, Chiminski had been president and CEO of GE Medical Diagnostics. Catalent is a leading contract packaging and drug-delivery provider.
Aptilon (Montreal), a provider of online sales channels to physicians, has named Wayne Musial as SVP, sales. Previously, Musial was EVP at Triple I, a MediMedia company.
The board of directors of CMR Institute (Roanoke, VA) has appointed Cherie G. Hicks, CPA, as president and CEO of the organization. CMR is a not-for-profit teaching organization in non-branded education for pharma professionals. She replaces James Dutton, who will remain as president emeritus.
Tagsys (Burlington, MA) has appointed Alain Fanet as CEO. Fanet replaces Bill Stuek, who will remain as chairman of the board. Tagsys develops RFID technology for product identification.
Thomas R. Bizzaro, RPh, has been promoted from VP of sales and marketing, to VP, health policy and industry relations at First DataBank (Indianapolis), a subsidiary of Hearst Corporation, which provides drug databases that are used within information systems that record utilization, pricing and reimbursement.
AbelsonTaylor (Chicago), the world’s largest independent advertising agency in healthcare, has promoted Kristen McGirk, Mark Finn and Eric Densmore from senior account supervisor roles to account directors in the agency’s ethical pharmaceuticals unit. Also: Jonathan Davila has been promoted, and Joseph Tiu hired, as senior copywriters. PC